QCM Cayman’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

QCM Cayman’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-3,048	Closed	-$30K	–	264
2017 Q2	$30K	Buy	+3,048	New	+$62.3K	0.07%	139

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

QCM Cayman's MACK Position: Q3 2017 in Review

QCM Cayman sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2017, closing a stake of 3,048 shares — an estimated $30K sold.

QCM Cayman first reported a position in MACK in Q2 2017 and held it in 1 quarter. The position peaked at $30K in Q2 2017. 73 funds tracked by Wall St. Rank hold MACK as of Q3 2017.

QCM Cayman reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
QCM Cayman sold 3,048 Merrimack Pharmaceuticals, Inc. shares in Q3 2017, an estimated $30K.
QCM Cayman first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2017 and held it in 1 quarter.
QCM Cayman's Merrimack Pharmaceuticals, Inc. position peaked at $30K in Q2 2017.
73 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2017.

Based on QCM Cayman's 13F filing for Q3 2017, filed 14 Nov 2017.